Pharma HS Codes and FDA Requirements

Pharmaceuticals are one of the most regulated import categories. The duty calculation is straightforward (most chapter 30 lines at 0 percent under the WTO Pharmaceutical Agreement), but the regulatory overlay dominates: FDA facility registration, Drug Master Files, GMP compliance, Drug Supply Chain Security Act (DSCSA) tracking, and prior notice filings. Get the regulatory side wrong and the duty calculation is irrelevant; your shipment will be refused entry.

This guide covers the chapter 30 structure, the WTO Pharmaceutical Agreement, the related chapters (29 for APIs, 38 for diagnostic reagents), and the FDA framework.

Chapter 30 structure

Chapter 30 has six headings:

• 3001: glands and other organs for organo-therapeutic uses, extracts.
• 3002: human and animal blood for therapeutic uses; antisera, vaccines, immunological products.
• 3003: medicaments (mixture of two or more constituents) other than retail forms.
• 3004: medicaments (mixed or unmixed) for retail sale.
• 3005: wadding, gauze, bandages, similar surgical articles.
• 3006: pharmaceutical goods including sterile surgical catgut, opacifying preparations for X-ray.

The key distinction within chapter 30 is between bulk medicaments (3003) and retail-form medicaments (3004). Retail form means presented for human or animal consumption in measured doses or in forms for direct use.

The WTO Pharmaceutical Agreement

The Pharmaceutical Agreement is a plurilateral arrangement under the WTO Trade in Pharmaceutical Products Initiative. It eliminates MFN tariffs on:

• A list of around 7,000 pharmaceutical products (active ingredients and finished forms).
• Approximately 1,200 chemical intermediates used in pharmaceutical manufacturing.

The list is updated periodically by adding new molecules as they reach therapeutic significance. The most recent material update was in 2010 (Round V); a Round VI has been proposed but not concluded.

For US imports, the Pharmaceutical Agreement zero-rate applies to listed compounds in chapter 29 (when imported as APIs) and listed finished forms in chapter 30. Specific HTS subheadings note "free" in the Pharmaceutical Appendix to the HTSUS.

Section 122 status

The February 2026 Section 122 proclamation, as amended in March 2026, exempts:

• Specified APIs: insulin (HTS 2937.31), salts of various antibiotics (HTS 2941.X subheadings), anti-retroviral building blocks, oncology generics certain subheadings.
• Specified finished dosage forms: insulin preparations (3004.31), vaccines (3002), anti-retroviral combinations, certain oncology products.

The full exemption list is in the proclamation's annex. For HTS lines not on the list, Section 122 at 15 percent applies even though MFN is 0 percent. Effectively, generic chronic-care medications still pay 15 percent unless on the carve-out.

Chapter 29 vs chapter 30: API vs finished

Chapter 29 (organic chemicals) covers pure chemical compounds. Chapter 30 (pharmaceuticals) covers therapeutic preparations.

• Paracetamol API (CAS 103-90-2) in bulk powder: HTS 2924.29 (chapter 29).
• Paracetamol 500mg tablets in retail bottle: HTS 3004.90 (chapter 30).
• Paracetamol API in bulk drum, identified for pharmaceutical use, in some cases: still chapter 29 unless formulated.

The boundary is whether the substance is formulated for therapeutic use. Bulk API: chapter 29. Formulated dosage form: chapter 30.

Worked example: 500,000 USD of generic acetaminophen tablets from India

A US importer brings in 500,000 USD of acetaminophen 500mg tablets in retail bottles from an Indian manufacturer. HTS 3004.90.91 (other medicaments containing paracetamol or similar, retail). MFN 0 percent under Pharmaceutical Agreement.

The product is on the Section 122 exemption list (generic over-the-counter analgesic).

Effective duty trivial. But the regulatory cost is the real story:

• FDA facility registration of the Indian manufacturer.
• DMF on file at FDA for paracetamol.
• GMP certification (USFDA-inspected facility).
• DSCSA serialization compliance (every package has a unique serialized number tracked through the supply chain).
• Prior notice (although for drugs the equivalent is import alert checks).
• Importer must hold an FDA-registered establishment for distribution.

The regulatory cost dominates the economics, not the duty.

FDA framework for drug imports

To legally import a drug into the US, the importer must satisfy:

1. Facility registration

The foreign manufacturing facility must be registered with FDA under 21 CFR 207. This involves:

• Annual registration fee.
• Listing all drugs manufactured at the facility.
• Subject to FDA inspection.

2. Drug listing

Each drug must be listed with FDA via the Structured Product Labeling (SPL) format.

3. Marketing approval

The drug must be approved for the US market through one of:

• New Drug Application (NDA) for new molecular entities.
• Abbreviated New Drug Application (ANDA) for generics.
• Biologics License Application (BLA) for biologicals.
• Over-the-counter monograph for OTC drugs.

Import of an unapproved drug is unlawful regardless of duty.

4. cGMP compliance

The facility must operate under current Good Manufacturing Practices (21 CFR Part 211 for finished pharmaceuticals, 21 CFR Part 600 for biologicals).

5. DSCSA

Drug Supply Chain Security Act requirements:

• Serialization at the saleable unit level.
• Aggregation of serialized units to cases and pallets.
• Transaction information, transaction history, and transaction statements (TI, TH, TS) for each transfer of ownership.
• As of November 2024, the interoperable, electronic, package-level tracking is in effect.

Imported drugs without DSCSA compliance are blocked from US distribution.

6. Import alert checks

FDA maintains import alerts on specific firms, products, and countries. A firm on detention without physical examination (DWPE) has its imports automatically detained pending review.

Customs entry process

For a pharmaceutical entry:

1. PN filing: not required for drugs per se (PN is for food), but a similar pre-entry notification through PREDICT is automatic.
2. Entry type 02: with FDA PGA message including:
   • FDA establishment identifier.
   • Affirmation of compliance code.
   • DEA registration if controlled substance.
3. Documentation: invoice, packing list, BoL, FDA-related documents.

FDA can examine, sample, or detain. Detained shipments require response within strict timelines.

High-risk subcategories

• Controlled substances (DEA Schedule I-V): require DEA import permit before entry. CSA registration required.
• Biologics: more stringent than small molecules. BLA-approved only.
• Compounded drugs: outsourcing facility registration required under DQSA Section 503B.
• Veterinary drugs: separate FDA Center (CVM) approval.

How the calculator handles pharma

The LandedFees calculator for pharmaceutical imports:

1. Classifies the HTS (chapter 29 API, chapter 30 finished, chapter 38 reagent).
2. Applies WTO Pharmaceutical Agreement zero rate where applicable.
3. Checks Section 122 exemption list.
4. Surfaces FDA regulatory hooks: facility registration, DMF, DSCSA, controlled substance.
5. Notes Prior Notice equivalent and PGA message requirements.

Related guides

• HS Code Lookup: How to Find Yours
• Chemistry HS Codes: Using CAS Numbers
• Cosmetics: HS Codes + MoCRA
• Food and Beverage HS Codes: FDA and FSVP
• Calculate Import Duty: India to USA
• Restricted Products: A Plain-English Guide

Try the LandedFees HS lookup tool for pharma classification.